Futuretech Ii Acquisition CORP 8-K filings

FutureTech II Acquisition Corp. announced a restatement of previously issued financial statements for multiple periods due to identified errors and misstatements.

FutureTech II Acquisition Corp.'s independent auditor, Adeptus Partners LLC, resigned effective January 12, 2026, citing material weaknesses and expressing substantial doubt about the company's ability to continue as a going concern.

FutureTech II Acquisition Corp. has terminated zero-interest convertible notes totaling $1.025 million with six investors, effective November 8, 2025, with no funds having been advanced to the company.

FutureTech II Acquisition Corp. provides an update on its merger with Longevity Biomedical, Inc., including a waiver allowing target Aegeria Soft Tissue, LLC to solicit alternative acquisition proposals.

FutureTech II Acquisition Corp. stockholders approved an extension of the deadline to complete an initial business combination until August 18, 2026.

FutureTech II Acquisition Corp. has entered into an amended and restated merger agreement with Longevity Biomedical, Inc. and Longevity Biomedical Holdings Corp. to form a combined entity expected to list on Nasdaq under 'LBIO' in Q4 2025.

FutureTech II Acquisition Corp. entered into agreements for $1.025 million in zero-interest convertible notes to fund operations until its initial business combination.

FutureTech II Acquisition Corp. obtains a $1.5 million loan from its sponsor to fund business combination expenses and operational costs, while trading over the counter following a Nasdaq suspension.

FutureTech II Acquisition Corp. received a delisting notice from Nasdaq after failing to complete a business combination within the required timeframe following its IPO.

FutureTech II Acquisition Corp. has received notification from Nasdaq that it has regained compliance with listing requirements, allowing its securities to remain listed on the exchange.

FutureTech II Acquisition Corp. reaches an agreement with D. Boral Capital to settle a deferred underwriting commission related to its IPO by using a combination of cash, a promissory note, and company stock, contingent on the closing of its business combination with Longevity Biomedical Inc.

FutureTech II Acquisition Corp. finalizes a subscription agreement and escrow agreement with Yuantian Zhang for a $5 million private placement tied to a business combination.

FutureTech II Acquisition Corp. reports an overpayment made to stockholders during the second extension redemption and is taking steps to recover the excess funds.

FutureTech II Acquisition Corp. has been granted an extension by Nasdaq to maintain its listing, contingent on filing its overdue 2024 3Q 10-Q report by January 31, 2025.

FutureTech II Acquisition Corp. reported overpayments in previous share redemptions and announced results from its third extension meeting, including a further extension to complete its business combination.

FutureTech II Acquisition Corp. will restate its financial statements for multiple periods due to accounting errors related to redemption prices and extension loans.

FutureTech II Acquisition Corp. has received approval to transfer its listing to the Nasdaq Capital Market, effective December 13, 2024.

FutureTech II Acquisition Corp. is at risk of being delisted from Nasdaq due to a delayed quarterly report and insufficient publicly held shares.

FutureTech II Acquisition Corp. is appealing a delisting notice from Nasdaq after failing to meet the minimum market value requirement, and is seeking to transfer its listing to the Nasdaq Capital Market.

FutureTech II Acquisition Corp. will restate its financial statements for 2023 and the first two quarters of 2024 due to errors in accounting for extension loans and potential overpayments in redemptions.

FutureTech II Acquisition Corp. has extended its deadline to complete a business combination to August 18, 2025, and modified the conversion rights of its Class B common stock to regain compliance with Nasdaq listing rules.

FutureTech II Acquisition Corp. is appealing a Nasdaq delisting notice after failing to meet the minimum market value requirement, with a hearing scheduled for December 17, 2024.

FutureTech II Acquisition Corp. is facing potential delisting from the Nasdaq Global Market after failing to maintain the minimum market value of listed securities.

FutureTech II Acquisition Corp. and Longevity Biomedical, Inc. have agreed to a business combination, with Longevity becoming a publicly traded company on the Nasdaq.

FutureTech II Acquisition Corp. has been granted an extension until May 31, 2024, to regain compliance with Nasdaq's minimum total holders rule.

FutureTech II Acquisition Corp. has received a notice from Nasdaq regarding its failure to meet the minimum market value requirement for continued listing.

FutureTech II Acquisition Corp. received a delisting notice from Nasdaq for failing to meet the minimum total holders requirement and plans to appeal the decision.

FutureTech II Acquisition Corp. has extended its deadline to complete a business combination by nine months, until November 18, 2024, following a shareholder vote and a related redemption of shares.